ArQule’s lead drug tivantinib flops again in PhIII liver cancer study
ArQule and Daiichi Sankyo’s tivantinib has come up short in another Phase III study.
Five years after the biotech’s lead drug flopped in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
